398 related articles for article (PubMed ID: 27989787)
21. Centromere 17 copy number gain reflects chromosomal instability in breast cancer.
Lee K; Kim HJ; Jang MH; Lee S; Ahn S; Park SY
Sci Rep; 2019 Nov; 9(1):17968. PubMed ID: 31784614
[TBL] [Abstract][Full Text] [Related]
22. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Marchiò C; Lambros MB; Gugliotta P; Di Cantogno LV; Botta C; Pasini B; Tan DS; Mackay A; Fenwick K; Tamber N; Bussolati G; Ashworth A; Reis-Filho JS; Sapino A
J Pathol; 2009 Sep; 219(1):16-24. PubMed ID: 19670217
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
24. The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Katayama A; Starczynski J; Toss MS; Shaaban AM; Provenzano E; Quinn CM; Callagy G; Purdie CA; Millican-Slater R; Purnell D; Chagla L; Oyama T; Pinder SE; Chan S; Ellis I; Lee AHS; Rakha EA
Histopathology; 2022 Oct; 81(4):511-519. PubMed ID: 35879836
[TBL] [Abstract][Full Text] [Related]
25. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort.
Koudelakova V; Trojanec R; Vrbkova J; Donevska S; Bouchalova K; Kolar Z; Varanasi L; Hajduch M
Genes Chromosomes Cancer; 2016 May; 55(5):409-17. PubMed ID: 26847577
[TBL] [Abstract][Full Text] [Related]
26. HER2 gene copy number and breast cancer-specific survival.
Biserni GB; Engstrøm MJ; Bofin AM
Histopathology; 2016 Nov; 69(5):871-879. PubMed ID: 27271096
[TBL] [Abstract][Full Text] [Related]
27. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
28. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
Page DB; Wen H; Brogi E; Dure D; Ross D; Spinelli KJ; Patil S; Norton L; Hudis C; McArthur HL
Breast Cancer Res Treat; 2018 Jan; 167(2):547-554. PubMed ID: 28986743
[TBL] [Abstract][Full Text] [Related]
29. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
[TBL] [Abstract][Full Text] [Related]
31. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
Viale G
J Pathol; 2009 Sep; 219(1):1-2. PubMed ID: 19670216
[TBL] [Abstract][Full Text] [Related]
32. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
33. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
34. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
Pritchard KI; Munro A; O'Malley FP; Tu D; Li X; Levine MN; Shepherd L; Chia S; Bartlett JM
Breast Cancer Res Treat; 2012 Jan; 131(2):541-51. PubMed ID: 22042366
[TBL] [Abstract][Full Text] [Related]
35. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
[TBL] [Abstract][Full Text] [Related]
36. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
38. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
[TBL] [Abstract][Full Text] [Related]
39. HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.
Holzschuh MA; Czyz Z; Hauke S; Inwald EC; Polzer B; Brockhoff G
Histopathology; 2017 Oct; 71(4):610-625. PubMed ID: 28502100
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome].
Zhang S; Wang Y; Guo ZM; Zhang H; Xu L; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):686-90. PubMed ID: 25331387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]